Midterm outcomes from a 1,000-patient, 42-site trial, published in the Journal of the American College of Cardiology, found the use of Boston Scientific's subcutaneous implantable cardioverter defibrillator continued to be effective and safe for treating patients with lethal ventricular arrhythmias at one year. The device demonstrated a 97.4% overall conversion success rate for discrete spontaneous episodes, as well as low implant complication rates.
Data show positive results for Boston Scientific's S-ICD
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.